Intensive Care Management of Sickle Cell Disease

@article{1707175,
      author = {Dr. Idowu Olusola K., Dr Sanusi A. A., Dr. Owoade O. A.},
      title = {Intensive Care Management of Sickle Cell Disease},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {8},
      number = {8},
      pages = {922-928},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1707175.pdf},
      abstract = {Sickle cell disease (SCD) is one of the most common hereditary disorders in the world, and it is most prevalent in the Middle East, the Mediterranean region, Southeast Asia, and sub-Saharan Africa, particularly in Nigeria. Sickle cell disease (SCD) is an autosomal recessive blood illness that is marked by clinical variability that may be influenced by environmental variables, racial and ethnic identity, socioeconomic status, and genetic and epigenetic factors. A variety of genotypes resulted in SCD characterized by the presence of one ?s gene and one of the following genes: another ?s (homozygous disease known as sickle cell anemia), a hemoglobin C gene, a gene for ?+ or ??-thalassemia or a hemoglobin D or hemoglobin E gene. Sickle cell anemia (SCA) is the most common genetic variant of SCD, accounting for 70% of cases worldwide.},
      month = {February},
  }